Abstract
The ability of functional imaging to detect and monitor metastatic disease in the skeleton, with advantages over conventional imaging such as bone scintigraphy or computed tomography (CT), has led to positron emission tomography (PET), particularly with the tracer 18F-fluorodeoxyglucose (18F-FDG), to be adopted into clinical practice. 18F-sodium fluoride (18F-NaF) is a bone-specific tracer with uptake related to local osteoblastic activity and mineralisation and may also be useful in breast, prostate and other cancers. The relationship between tumour activity and osteoblastic activity in skeletal metastases may therefore be complex and a careful assessment with full knowledge of the length and type of therapy is essential to accurately monitor disease response.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cook GJ, Azad GK, Goh V. Imaging bone metastases in breast cancer: staging and response assessment. J Nucl Med. 2016;57(Suppl 1):27S–33S.
Mahajan A, Azad GK, Cook GJ. PET imaging of skeletal metastases and its role in personalizing further management. PET Clin. 2016;11:305–18.
Azad GK, Cook GJ. Multi-technique imaging of bone metastases: spotlight on PET-CT. Clin Radiol. 2016;71:620–31.
Cook GJ, Goh V. Functional and hybrid imaging of bone metastases. J Bone Miner Res. 2018;33:961–72.
Azad GK, Taylor BP, Green A, Sandri I, Swampillai A, Harries M, Kristeleit H, Mansi J, Goh V, Cook GJR. Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [(18)F] fluorodeoxyglucose and [(18)F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging. Eur J Nucl Med Mol Imaging. 2019;46:821–30.
Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology. 2008;247:189–96.
Specht J, Tam S, Kurland B, Gralow JR, Livingston RB, Linden HM, et al. Serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat. 2007;105:87–94.
Cook GJ, Azad G, Padhani AR. Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology. Clin Transl Imaging. 2016;4:439–47.
Azad GK, Taylor B, Rubello D, Colletti PM, Goh V, Cook GJ. Molecular and functional imaging of bone metastases in breast and prostate cancers: an overview. Clin Nucl Med. 2016;41:e44–50.
Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, et al. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687. J Nucl Med. 2015;56:354–60.
Harmon SA, Perk T, Lin C, Eickhoff J, Choyke PL, Dahut WL, et al. Quantitative assessment of early [18F]sodium fluoride positron emission tomography/computed tomography response to treatment in men with metastatic prostate cancer to bone. J Clin Oncol. 2017;35:2829–37.
Hillner BE, Siegel BA, Hanna L, Duan F, Quinn B, Shields AF. 18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry. J Nucl Med. 2015;56:222–88.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Cook, G.J.R., Usmani, S. (2021). 18F-FDG PET-CT and 18F-NaF in Treatment Response Evaluation: Bone Metastases and Bone Tumours. In: Fanti, S., Gnanasegaran, G., Carrió, I. (eds) Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-68858-5_24
Download citation
DOI: https://doi.org/10.1007/978-3-030-68858-5_24
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-68857-8
Online ISBN: 978-3-030-68858-5
eBook Packages: MedicineMedicine (R0)